Analytical similarity as base for rituximab biosimilars in lymphoid malignancies in the clinic: a PF-05280586 case study. Supplementary figures and table.
figure
posted on 2022-01-24, 10:25 authored by Jeff P Sharman, Robert M. Rifkin, Carol F. Kirchhoff
Supplemental Table S1. Summary of safety findings from REFLECTIONS B328-06 study [2]. (© The Author(s) 2019. https://creativecommons.org/licenses/by-nc/4.0/)
|
Supplemental Figure S2. Study design (REFLECTIONS B328-06) [2]. (© The Author(s). https://creativecommons.org/licenses/by-nc/4.0/) Supplemental Figure S3. Incidence of anti-drug antibodies (safety population). Created using data from [2]. |